Clinical Trials

Breast Neoplasms, Patient Compliance

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

327 enrolled

Breast Neoplasms

NCT03822468 2025-10-16

AMALEE

376 enrolled 17 charts

Breast Neoplasms

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

315 enrolled 11 charts

Breast Neoplasms

NCT03839823 2024-10-09

RIGHT Choice

222 enrolled 17 charts

Breast Neoplasms

NCT05163106 2024-08-02

NEOLETRIB

85 enrolled

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

55 enrolled 15 charts

Breast Neoplasms

NCT00295646 2024-03-15

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

1,803 enrolled 20 charts

Breast Neoplasms

NCT02278120 2024-03-12

MONALEESA-7

672 enrolled 16 charts 1 FDA

Advanced Metastatic Breast Cancer

NCT02941926 2023-10-24

COMPLEEMENT-1

3,246 enrolled 11 charts

Breast Neoplasms

NCT00309478 2023-06-29

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

1,099 enrolled

Breast Neoplasms

NCT02333370 2023-06-08

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Phase 1 Completed

88 enrolled

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

NCT05110170 2023-05-16

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

188 enrolled

Breast Neoplasms

NCT00432172 2023-04-03

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

189 enrolled 17 charts

Breast Neoplasms

NCT03447132 2023-03-10

SAFIA

354 enrolled

Breast Neoplasms

NCT01989780 2022-08-04

BOOSTER

160 enrolled

Breast Neoplasms

NCT03628066 2022-04-20

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

24 enrolled

Breast Neoplasms

NCT02586675 2022-01-21

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Phase 1 Completed

7 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT03096847 2021-10-11

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

502 enrolled 20 charts

Breast Neoplasms, Osteitis Deformans

NCT02518191 2021-06-11

Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

345 enrolled 9 charts

Breast Neoplasms

NCT00068601 2019-12-30

S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

257 enrolled 8 charts

Breast Neoplasms, Infertility

NCT00186121 2019-10-07

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

35 enrolled 11 charts

Breast Neoplasms

NCT01073865 2018-12-12

Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer

222 enrolled 13 charts

Breast Neoplasms

NCT01638247 2018-09-19

MALE

56 enrolled

Breast Neoplasms, Male

NCT02483767 2017-10-17

POF

98 enrolled

Breast Neoplasms

NCT01712893 2017-08-25

Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer

216 enrolled

Breast Neoplasms

NCT00010010 2016-03-11

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer

Breast Neoplasms

NCT01530607 2016-02-25

Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer

416 enrolled

Breast Neoplasms

NCT00002580 2013-11-06

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

1,000 enrolled

Breast Neoplasms

NCT00427245 2013-08-07

Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer

400 enrolled

Breast Neoplasms, Infertility

NCT00002582 2013-08-02

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

6,000 enrolled

Breast Neoplasms

NCT00031850 2013-06-26

Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer

Phase NA Completed

150 enrolled

Breast Neoplasms

NCT00047099 2013-05-30

Combination Chemotherapy in Treating Women With Breast Cancer

446 enrolled

Breast Neoplasms

NCT00605267 2012-09-06

Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

197 enrolled 23 charts

Breast Neoplasms, Neoplasms

NCT00827307 2011-08-08

Zoladex Plus Tamoxifen in Breast Cancer

Phase NA Completed

100 enrolled

Breast Neoplasms, Hyperlipidemias

NCT00532272 2011-06-27

Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC

78 enrolled

Breast Neoplasms

NCT00322348 2011-01-24

Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

98 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT00235937 2011-01-21

Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex

45 enrolled

Breast Neoplasms

NCT00196846 2010-06-14

Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)

62 enrolled

Breast Neoplasms

NCT00303524 2009-12-23

Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

170 enrolled